AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial-Reference-Cited by-同舟云学术

AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial

Author:

Lipton Richard B.¹²³,McGinley James S.⁴,Shulman Kenneth J.⁵,Silberstein Stephen D.⁶,Wirth R. J.⁴,Buse Dawn C.¹³

Affiliation:

1. Department of Neurology Albert Einstein College of Medicine and Montefiore Headache Center; Bronx NY USA

2. Department of Epidemiology and Population Health; Albert Einstein College of Medicine; Bronx NY USA

3. Montefiore Medical Center; Bronx NY USA

4. Vector Psychometric Group, LLC; Chapel Hill NC USA

5. Avanir Pharmaceuticals, Inc.; Aliso Viejo CA USA

6. Thomas Jefferson University; Philadelphia PA USA

Funder

Avanir Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

Reference27 articles.

1. The International Classification of Headache Disorders, 3rd edition (beta version);Headache Classification Committee of the International Headache Society (IHS);Cephalalgia.,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Migraine and Gastroparesis;Current Neurology and Neuroscience Reports;2022-11-12